Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

Bruce L. Levine; Marcelo C. Pasquini; John E. Connolly; David L. Porter; Michael P. Gustafson; Jaap J. Boelens; Edwin M. Horwitz; Stephan A. Grupp; Marcela V. Maus; Frederick L. Locke; Fabio Ciceri; Annalisa Ruggeri; John Snowden; Helen E. Heslop; Crystal L. Mackall; Carl H. June; Anna M. Sureda; Miguel Angel Perales

doi:10.1038/s41591-023-02767-w

Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

Bruce L. Levine, Marcelo C. Pasquini, John E. Connolly, David L. Porter, Michael P. Gustafson, Jaap J. Boelens, Edwin M. Horwitz, Stephan A. Grupp, Marcela V. Maus, Frederick L. Locke, Fabio Ciceri, Annalisa Ruggeri, John Snowden, Helen E. Heslop, Crystal L. Mackall, Carl H. June, Anna M. Sureda, Miguel Angel Perales

Research output: Contribution to journal › Comment/debate › peer-review

68 Scopus citations

Abstract

Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.

Original language	English (US)
Pages (from-to)	338-341
Number of pages	4
Journal	Nature Medicine
Volume	30
Issue number	2
DOIs	https://doi.org/10.1038/s41591-023-02767-w
State	Published - Feb 2024

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1038/s41591-023-02767-w

Cite this

Levine, B. L., Pasquini, M. C., Connolly, J. E., Porter, D. L., Gustafson, M. P., Boelens, J. J., Horwitz, E. M., Grupp, S. A., Maus, M. V., Locke, F. L., Ciceri, F., Ruggeri, A., Snowden, J., Heslop, H. E., Mackall, C. L., June, C. H., Sureda, A. M., & Perales, M. A. (2024). Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nature Medicine, 30(2), 338-341. https://doi.org/10.1038/s41591-023-02767-w

Levine, BL, Pasquini, MC, Connolly, JE, Porter, DL, Gustafson, MP, Boelens, JJ, Horwitz, EM, Grupp, SA, Maus, MV, Locke, FL, Ciceri, F, Ruggeri, A, Snowden, J, Heslop, HE, Mackall, CL, June, CH, Sureda, AM & Perales, MA 2024, 'Unanswered questions following reports of secondary malignancies after CAR-T cell therapy', Nature Medicine, vol. 30, no. 2, pp. 338-341. https://doi.org/10.1038/s41591-023-02767-w

@article{fe4da267e71244929ee10dfd87c1da6a,

title = "Unanswered questions following reports of secondary malignancies after CAR-T cell therapy",

abstract = "Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.",

author = "Levine, {Bruce L.} and Pasquini, {Marcelo C.} and Connolly, {John E.} and Porter, {David L.} and Gustafson, {Michael P.} and Boelens, {Jaap J.} and Horwitz, {Edwin M.} and Grupp, {Stephan A.} and Maus, {Marcela V.} and Locke, {Frederick L.} and Fabio Ciceri and Annalisa Ruggeri and John Snowden and Heslop, {Helen E.} and Mackall, {Crystal L.} and June, {Carl H.} and Sureda, {Anna M.} and Perales, {Miguel Angel}",

note = "Publisher Copyright: {\textcopyright} Springer Nature America, Inc. 2024.",

year = "2024",

month = feb,

doi = "10.1038/s41591-023-02767-w",

language = "English (US)",

volume = "30",

pages = "338--341",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

AU - Levine, Bruce L.

AU - Pasquini, Marcelo C.

AU - Connolly, John E.

AU - Porter, David L.

AU - Gustafson, Michael P.

AU - Boelens, Jaap J.

AU - Horwitz, Edwin M.

AU - Grupp, Stephan A.

AU - Maus, Marcela V.

AU - Locke, Frederick L.

AU - Ciceri, Fabio

AU - Ruggeri, Annalisa

AU - Snowden, John

AU - Heslop, Helen E.

AU - Mackall, Crystal L.

AU - June, Carl H.

AU - Sureda, Anna M.

AU - Perales, Miguel Angel

PY - 2024/2

Y1 - 2024/2

N2 - Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.

AB - Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.

UR - http://www.scopus.com/inward/record.url?scp=85181956361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85181956361&partnerID=8YFLogxK

U2 - 10.1038/s41591-023-02767-w

DO - 10.1038/s41591-023-02767-w

M3 - Comment/debate

C2 - 38195751

AN - SCOPUS:85181956361

SN - 1078-8956

VL - 30

SP - 338

EP - 341

JO - Nature Medicine

JF - Nature Medicine

IS - 2

ER -

Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this